Nonhematopoietic IRAK1 drives arthritis via neutrophil chemoattractants
Authors:
- Thomas HoylerTHThomas Hoyler
- Bettina BannertBBBettina Bannert
- Cédric AndréCACédric André
- Damian BeckDBDamian Beck
- Thomas BoulayTBThomas Boulay
- David BuffetDBDavid Buffet
- Nadja CaesarNCNadja Caesar
- Thomas CalzasciaTCThomas Calzascia
- Janet DawsonJDJanet Dawson
- Diego KyburzDKDiego Kyburz
- Robert HennzeRHRobert Hennze
- Christine HuppertzCHChristine Huppertz
Open Access
- 8 July 2022
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 7 (13)
Abstract
IL-1 receptor-activated kinase 1 (IRAK1) is involved in signal transduction downstream of many TLRs and the IL-1R. Its potential as a drug target for chronic inflammatory diseases is underappreciated. To study its functional role in joint inflammation, we generated a mouse model expressing a functionally inactive IRAK1 (IRAK1 kinase deficient, IRAK1KD), which also displayed reduced IRAK1 protein expression and cell type–specific deficiencies of TLR signaling. The serum transfer model of arthritis revealed a potentially novel role of IRAK1 for disease development and neutrophil chemoattraction exclusively via its activity in nonhematopoietic cells. Consistently, IRAK1KD synovial fibroblasts showed reduced secretion of neutrophil chemoattractant chemokines following stimulation with IL-1β or human synovial fluids from patients with rheumatoid arthritis (RA) and gout. Together with patients with RA showing prominent IRAK1 expression in fibroblasts of the synovial lining, these data suggest that targeting IRAK1 may be therapeutically beneficial. As pharmacological inhibition of IRAK1 kinase activity had only mild effects on synovial fibroblasts from mice and patients with RA, targeted degradation of IRAK1 may be the preferred pharmacologic modality. Collectively, these data position IRAK1 as a central regulator of the IL-1β–dependent local inflammatory milieu of the joints and a potential therapeutic target for inflammatory arthritis.Keywords
Funding Information
- Novartis (NA)
This publication has 67 references indexed in Scilit:
- Neutrophils orchestrate their own recruitment in murine arthritis through C5aR and FcγR signalingProceedings of the National Academy of Sciences, 2012
- Lipid-Cytokine-Chemokine Cascade Drives Neutrophil Recruitment in a Murine Model of Inflammatory ArthritisImmunity, 2010
- Deficiency of CXCR2, but not other chemokine receptors, attenuates autoantibody‐mediated arthritis in a murine modelArthritis & Rheumatism, 2010
- The role of pattern-recognition receptors in innate immunity: update on Toll-like receptorsNature Immunology, 2010
- Fibroblast‐like synoviocytes: key effector cells in rheumatoid arthritisImmunological Reviews, 2009
- Identification ofIRAK1as a risk gene with critical role in the pathogenesis of systemic lupus erythematosusProceedings of the National Academy of Sciences, 2009
- TLR7-dependent and FcγR-independent production of type I interferon in experimental mouse lupusJournal of Experimental Medicine, 2008
- Duffy antigen receptor for chemokines and CXCL5 are essential for the recruitment of neutrophils in a multicellular model of rheumatoid arthritis synoviumArthritis & Rheumatism, 2008
- Cytokines in the pathogenesis of rheumatoid arthritisNature Reviews Immunology, 2007
- Mast cells contribute to initiation of autoantibody-mediated arthritis via IL-1Proceedings of the National Academy of Sciences, 2007